期刊文献+

缬沙坦对冠心病患者颈动脉斑块及血清高敏C反应蛋白的影响 被引量:9

Effects of valsartan on the carotid artery atherosclerotic plaques and the serum hs-CRP in patients with coronary artery disease
原文传递
导出
摘要 目的:探讨缬沙坦坦对冠心病患者颈动脉内膜中层厚度(IMT)及颈动脉斑块的影响。方法:177例冠心病患者随机分为两组,治疗组服用缬沙坦80~160mg/d,对照组给予安慰剂。对照组中合并高血压者给予其他降压药(除外血管紧张素Ⅱ受体拮抗剂和血管紧张素转化酶抑制剂)。两组患者血压均控制在140/90mmHg(1mmHg=0.133kPa)以下。治疗前后以彩色多普勒超声检测所有患者IMT及颈动脉斑块,并测定血清高敏C反应蛋白(hs-CRP)水平,同时观察冠心病事件发生率和冠状动脉(冠脉)血运重建率。结果:24个月后,治疗组颈动脉IMT值、血清hs-CRP以及颈动脉斑块大小、数量和厚度均较治疗前明显下降(均P〈0.01)。对照组颈动脉IMT值、血清hs-CRP以及颈动脉斑块大小、数量和厚度呈下降趋势,但差异无统计学意义。随访期间,治疗组冠心病事件发生率和冠脉血运重建率明显低于对照组。结论:血管紧张素Ⅱ受体拮抗剂缬沙坦能逆转动脉粥样硬化,抑制斑块内炎症反应,消退动脉斑块,降低冠心病事件发生率和冠脉血运重建率。 Objective:To evaluate the clinical antiatheroscleosis effects of valsartan on atherosclerotic carotid artery in patients with coronary artery disease.Method:All 177patients with coronary artery disease were randomed to therapy group and control group.The patients in therapy group were recieved with valsartan 80~160mg/d. The placebos were given to the control group.Patients with hypertension in cantrol group were treated with other antihypertensive drugs except angiotensin-converting enzyme inhibitor and angiotensinⅡ receptor blocker.Blood presure of patients in two groups were controlled under 140/90mmHg(1mmHg=0.133kPa).The carotid intima-media thickness(IMT)and atherosclerotic plaques were measured with color Doppler ultrasonograms before and after 24 months treatment.The serum hs-CRP was also determined.The ratio of coronary heart disease events and coronary revascularization were observed.Result:The IMT and the size,quantity and thickness of carotid atherosclerotic plaques,the serum hs-CRP in therapy group were decreased more significantly than those in control group.During follow-up period,the ratio of coronary heart disease events and coronary revascularization in therapy group was significantly lower than those in control group.Conclusion:Valsartan can decrease IMT and the ratio of coronary heart disease events and coronary revascularization,and inhibit the inflammatory reaction of atherosclerotic plaques and reverse carotid atherosclerotic plaques after long time treatment.
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2014年第2期135-137,共3页 Journal of Clinical Cardiology
关键词 冠心病 动脉粥样硬化 缬沙坦 颈动脉内膜中层厚度 coronary artery disease atheroscleosis valsartan intima-media thickness
作者简介 通信作者:马志强,E-mail:MZQY1967@TOM.com
  • 相关文献

参考文献10

  • 1马志强,刘力,成蓓,王志权.血管紧张素Ⅱ对巨噬细胞和泡沫细胞ACAT-1及PPAR-γ表达的影响[J].心脏杂志,2011,23(2):169-172. 被引量:1
  • 2马志强,成蓓,丁宇慧,曾永利.缬沙坦对兔动脉粥样硬化斑块中ACAT-1和PPAR-γ表达的影响[J].解放军医学杂志,2008,33(9):1105-1108. 被引量:4
  • 3马志强,成蓓,曾永利,丁宇慧.缬沙坦对动脉粥样硬化兔核因子κB和单核细胞趋化因子-1的影响[J].微循环学杂志,2008,18(3):28-31. 被引量:7
  • 4Fisnik Jashari,Pranvera Ibrahimi,Rachel Nicoll,Gani Bajraktari,Per Wester,Michael Y. Henein.Coronary and carotid atherosclerosis: Similarities and differences[J].Atherosclerosis.2012
  • 5Nadine Nagy,Ariane Melchior-Becker,Jens W. Fischer.Long-term treatment with the AT1-receptor antagonist telmisartan inhibits biglycan accumulation in murine atherosclerosis[J].Basic Research in Cardiology.2010(1)
  • 6Bertine M.B. Goessens,Frank L.J. Visseren,L Jaap Kappelle,Ale Algra,Yolanda van der Graaf.Asymptomatic Carotid Artery Stenosis and the Risk of New Vascular Events in Patients With Manifest Arterial Disease: The SMART Study[J].Stroke.2007(5)
  • 7EigilFossum,Michael HechtOlsen,AudH?ieggen,KristianWachtell,Henrik M.Reims,Sverre E.Kjeldsen,HansIbsen,YingWan,StevoJulius.Long‐Term Effects of a Losartan‐Compared With an Atenolol‐Based Treatment Regimen on Carotid Artery Plaque Development in Hypertensive Patients With Left Ventricular Hypertrophy: ICARUS, a LIFE Substudy[J].The Journal of Clinical Hypertension.2007(3)
  • 8Huang Fei,Thompson Joel C,Wilson Patricia G,Aung Hnin H,Rutledge John C,Tannock Lisa R.Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development[].Journal of Lipid Research.2007
  • 9Hideto Yano,Kiyoshi Hibi,Naoki Nozawa.Effects of Valsartan, an Angiotensin II Receptor Blocker, on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction Who Receive an Angiotensin-Converting Enzyme Inhibitor[].Circulation Journal.2012
  • 10FUJIHARA K,SUZUKI H,SATO A,et al.Carotid artery plaque and LDL-to-HDL cholesterol ratio predict atherosclerotic status in coronary arteries in asymptomatic patients with Type 2diabetes mellitus[].Journal of Atherosclerosis and Thrombosis.2013

二级参考文献34

  • 1何平,成蓓,王毅,王洪星.乙酰化低密度脂蛋白促进胆固醇酰基转移酶活性升高的机制研究[J].临床心血管病杂志,2004,20(8):470-472. 被引量:4
  • 2唐哨勇,蒋学俊,李艳,王世敏,江洪.卡维地洛对高血压大鼠主动脉的保护作用[J].微循环学杂志,2005,15(1):10-12. 被引量:5
  • 3何平,成蓓,王洪星,戚本玲.酰基辅酶A胆固醇酰基转移酶1基因过表达对泡沫细胞形成的影响[J].中国动脉硬化杂志,2007,15(5):325-328. 被引量:7
  • 4Libby P. Current concepts of the pathogenesis of the acute corona syndrome. Circulation, 2001,104(3):365 -372.
  • 5Wilson SH, Best PJ,Edwards WD, et al. Nuclear factor kappaB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris. Atherosclerosis,2002,160(1):147-153.
  • 6Mitani H,Bandoh T,Kimura M,et al. Increased activity of vascular ACE related to atherosclerotic lesions in hyperlipidemic rabbit. Am J Physiol, 1996,271(3 pt 2):1 065-1 071.
  • 7Paradis P, Dali-Youcef N, Paradis FW, et al. Overexpression of angiotensin Ⅱ type Ⅰ receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Aead Sci USA,2000, 97 (2):931-936.
  • 8Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis, 1999,147(2) :213-225.
  • 9Inoue S, Egashira K, Ni W, et al. Anti-monocyte chemoattractant protein 1 gene therapy limits progression and destabilization of established atheroselerosis in apolipoprotein E-knockout mice. Circulation,2002,106(21) :2 700-2 706.
  • 10Monaco C, Andreakos E,Kiriakidis S,et al. Canonical pathway of nuclear factor kappa B activation lectively regulates proinflammatory and prothrombotic responses human atherosclerosis. Proc Natl Pcad Sci UsA ,2004,101(15):5 634-5 639.

共引文献8

同被引文献81

引证文献9

二级引证文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部